Agents and Actions

, Volume 7, Issue 1, pp 133–144 | Cite as

AHR-5850: A potent anti-inflammatory compound

  • Lawrence F. Sancilio
  • Donna L. Reese
  • Stephen Cheung
  • Reevis S. Alphin
Immunosuppression and Inflammation


AHR-5850 is a non-steroidal anti-inflammatory compound possessing antipyretic and analgesic properties. AHR-5850 was 16.4 and 22.8 times more potent than phenylbutazone in suppressing acute (Evans blue-carrageenan pleural effusion) and chronic (adjuvant-induced arthritis) inflammation, respectively. The analgesic activity of AHR-5850 was 43 times that of acetylsalicylic acid in the Randall-Selitto assay, and 156 and 56.3 times more potent than phenylbutazone in the acetylcholine-induced nociceptive response in dogs, respectively. Single-dose studies showed that AHR-5850 produced less gastric irritation than acetylsalicylic acid when applied topically to the exposed gastric mucosa of cats or when administered orally to rats and dogs. Upon subchronic oral administration to rats, the therapeutic ratio of AHR-5850 was twice that of phenylbutazone. This was based on the ratio of its potency relative to phenylbutazone in producing intestinal lesions to its anti-inflammatory potency relative to phenylbutazone in the adjuvant-induced arthritis.


Arthritis Oral Administration Pleural Effusion Gastric Mucosa Acetylsalicylic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    L.F. Sancilio andA. Fishman,Application of Sequential Analysis to Evans Blue-Carrageenan-Induced Pleural Effusion for Screening Compounds for Anti-Inflammatory Activity, Toxicol. Appl. Pharmac.26, 575–584 (1973).Google Scholar
  2. [2]
    L.F. Sancilio, unpublished data.Google Scholar
  3. [3]
    L.F. Sancilio andR. Rodriquez,Effect of Non-steroidal Anti-Inflammatory Drugs in the Evans Blue Pleural Effusion, Proc. Soc. exp. Biol. Med.123, 707–710 (1966).PubMedGoogle Scholar
  4. [4]
    C.A. Winter, E.A. Risley andG.W. Nuss,Carrageenan-Induced Edema in the Hind Paw of the Rat as an Assay for Anti-Inflammatory Drugs, Proc. Soc. exp. Biol. Med.111, 544–547 (1962).PubMedGoogle Scholar
  5. [5]
    D.T. Walz, M.J. DiMartino andA. Misher,Adjuvant-Induced Arthritis in Rats. II. Drug Effect on Physiologic, Biochemical, and Immunologic Parameters, J. Pharmac. exp. Ther.178, 223–231 (1971).Google Scholar
  6. [6]
    A.J. Anderson,The Effect of Antiinflammatory Drugs on the Enzymic Activity of a Rat Liver Granular Fraction which Increases Vascular Permeability, Biochem. Pharmac.17, 2253–2264 (1968).Google Scholar
  7. [7]
    A. Boyum,Isolation of Leucocytes from Human Blood. Further Observations, Methylcellulose, Dextran, and Ficoll Erythrocyte Aggregative Agents, Scand. J. Clin. Lab. Invest.21 (Suppl. 97), 31–50 (1968).Google Scholar
  8. [8]
    H.O.J. Collier, L.C. Dunneen, C.A. Johnson andC. Schneider,The Abdominal Constriction Response and the Suppression by Analgesic, Drugs in the Mouse, Br. J. Pharmac. Chemother.32, 295–310 (1968).Google Scholar
  9. [9]
    L.O. Randall andJ.J. Selitto,A Method for Measurement of Analgesic, Activity on Inflamed Tissue, Archs. int. Pharmacodyn. Thér.111, 409–419 (1957).Google Scholar
  10. [10]
    K.S. Swingle, T.S. Grant andD.C. Kvam,Quantal Responses in the Randall and Selitto Assay, Proc. Soc. exp. Biol. Med.137, 536–538 (1971).Google Scholar
  11. [11]
    G.D. Dickerson, R.J. Engle, F. Guzman, D.W. Rodgers andR.K.S. Lim,The Intraperitoneal Bradykinin-Evoked Pain Test for Analgesia. Life Sci.4, 2063–2069 (1965).PubMedGoogle Scholar
  12. [12]
    L.F. Sancilio andS. Cheung,Bradykinin Analgesic Test in Dogs: Oral Activity of AHR-5850 (2-Amino-3-benzoylphenyl Acetate Sodium), Indomethacin, Phenylbutazone and Acetylsalicylic Acid, Fed. Proc.35, 774 (1976).Google Scholar
  13. [13]
    P.K. Smith andW.E. Hambourger,The Ratio of the Toxicity of Acetanilid to its Antipyretic Activity in Rats, J. Pharmac. exp. Ther.54, 346–351 (1935).Google Scholar
  14. [14]
    M.E. Rosenthale, A.J. Begany, A. Dervinis, J.L. Malis, D.A. Shriver, L.J. Datko, andM.I. Gluckman,Antiinflammatory Properties of 4,5-Diphenyl-2-oxazole-propionic Acid, Agents and Actions4, 151–159 (1974).PubMedGoogle Scholar
  15. [15]
    F.L. Schmidt, G.J. Squiers andA. McElheny,Computerization of an Automated High-Volume Pharmaceutical Screen, Adv. Autom. Chem.9, 107–110 (1973).Google Scholar
  16. [16]
    R.S. Alphin andD.A. Droppleman,New Method for Evaluating Topical Action of Substances on Gastric Mucosa. J. Pharm. Sci.60, 1314–1316 (1971).PubMedGoogle Scholar
  17. [17]
    C.W. Dunnett A Multiple Comparison Procedure for Comparing Several Treatments with a Control, J. Amer. stat. Ass.50, 1096–1121 (1955).Google Scholar
  18. [18]
    A. Goldstein,Biostatistics, An Introductory Text, The MacMillan Company, New York (1964).Google Scholar
  19. [19]
    C. Bliss,Vitamin Methods (Ed. P. György: Academic Press, New York, 1951), Vol. 2.Google Scholar
  20. [20]
    A. Winer,Statistical Principles in Experimental Design, 2nd Ed., McGraw Hill Book Co., New York.Google Scholar
  21. [21]
    L.F. Sancilio,Evans Blue-Carrageenan Pleural Effusion as a Model for the Assay of Nonsteroidal Antirheumatic Drugs, J. Pharmac. exp. Ther.168, 199–204 (1969).Google Scholar
  22. [22]
    K.S. Swingle, T.J. Grant, L.W. Jacques andD.C. Kvam,Interactions of Antiinflammatory Drugs in Carrageenan-Induced Foot Edema of the Rat, J. Pharmac. exp. Ther.172, 423–425 (1970).Google Scholar
  23. [23]
    J.L. Granda, C.S. Ranat andA.S. Posner,Levels of Three Hydrolases in Rheumatoid and Regenerated Synovium, Arthritis Rheum.14, 223–230 (1971).PubMedGoogle Scholar
  24. [24]
    G. Opelz, P.I. Terosaki andA.A. Hirata,Suppression of Lymphocyte Transformation by Aspirin, Lancet2, 478–480 (September 1973).PubMedGoogle Scholar
  25. [25]
    M.J. Smith, M. Hoth andK. Davis,Aspirin and Lymphocyte Transformation, Ann. intern. Med.83, 509–511 (1975).PubMedGoogle Scholar
  26. [26]
    C.A. Stone, C.G. Van Arman, H.M. Peck, D.H. Minsker andE.A. Ham,Pharmacologic and Toxicologic Actions of Prostaglandin Synthetase Inhibitors. Potential Role of Prostaglandin Synthetase Inhibitors — their Effects on Physiological Functions and Pathological States (Eds. Harry J. Robinson and John R. Vane; Raven Press, New York, 1974).Google Scholar
  27. [27]
    M. McDougal,Interactions of Drugs with Aspirin, J. Am. Pharm. Ass.10, 83–85 (1970).Google Scholar
  28. [28]
    M.F. Cuthlert,Adverse Reactions to Non-Steroidal Antirheumatic Drugs, Curr. Med. Res. Opin.2, 600–609 (1975).Google Scholar

Copyright information

© Birkhäuser Verlag 1977

Authors and Affiliations

  • Lawrence F. Sancilio
    • 1
  • Donna L. Reese
    • 1
  • Stephen Cheung
    • 1
  • Reevis S. Alphin
    • 1
  1. 1.Pharmacological Research LaboratoryA. H. Robins Co., Inc.Richmond

Personalised recommendations